Michael Schmertzler

Michael Schmertzler is an accomplished professional with extensive experience in biotechnology, investment, and education. Currently serving as a Charter Trustee at Phillips Academy and Chairman of the Board at SHY Therapeutics and PTC Therapeutics, Schmertzler has a significant role in developing innovative cancer therapeutics. In addition, Michael is a Board Member at Berryville Holdings, LLC, and has contributed to academia as a Lecturer at Yale University. With past leadership positions including CEO of Kolltan Pharmaceuticals and managing director roles at Credit Suisse First Boston and Morgan Stanley, Schmertzler brings a wealth of knowledge in finance and corporate governance. Educational credentials include an MBA from Harvard Business School, as well as degrees from Princeton University and Yale University.